Washington State's 2025 bill to establish a licensed supervised psilocybin therapy system — a major West Coast state following in Oregon's footsteps.
Washington SB 5201 would create a regulated, supervised psilocybin program under the Department of Health and the Liquor and Cannabis Board. Adults 21 and older could access psilocybin services at a licensed facility with a trained facilitator — no retail sales, no home use.
The bill's official short title is the Clinical and Supervised Access to Psilocybin Act. It was prefiled January 9, 2025, and has broad bipartisan support with 14 Senate sponsors and a 29-sponsor companion House bill, HB 1433.
The program would launch with psilocybin and psilocin. Starting in 2030, the new Washington Psychedelic Substances Board could recommend adding other substances — a future-proofing mechanism similar to Colorado's advisory board model.
SB 5201's sponsors studied Oregon's Measure 109 closely. Oregon's program launched service centers in 2023 — the first legal supervised psilocybin program in the US. By early 2025, about 10,000 clients had been dosed through roughly 24 service centers and 377 licensed facilitators.
But Oregon's program revealed a critical gap: a single session costs over $1,000 to $2,000 out of pocket. Insurance does not cover it because psilocybin is still illegal under federal law. SB 5201 names affordability as a core legislative goal in the bill's own findings section — something Oregon's measure did not address.
Washington SB 5201 creates two distinct access tracks — a clinical track and a wellness track — which is the biggest structural difference from Oregon's single-tier model.
The clinical track serves adults who have a physician's recommendation and a diagnosed condition such as PTSD, treatment-resistant depression, or obsessive-compulsive disorder. A clinical facilitator — who must hold a Washington healthcare professional license — supervises the session.
This track gives people with serious mental health conditions access to a more medically supervised environment. It also creates a pathway that medical professionals already skeptical of psilocybin can engage with on familiar terms.
The wellness track is open to any adult 21 or older — no diagnosis, no referral. A wellness facilitator (who need not hold a clinical license) supervises the session and takes a non-directive approach: supporting safety without influencing the client's experience.
This is the affordability path. Group wellness sessions are expected to cost less than one-on-one clinical sessions. Washington lawmakers built this in directly after Oregon showed that a single-track clinical model prices out most people who could benefit.
SB 5201 sets two tiers of facilitator licensure with meaningfully different training requirements — one of the most detailed facilitator frameworks of any US psilocybin bill to date.
A wellness facilitator must complete an approved training program, a 50-hour in-person practicum, a state-approved exam, and 200 hours of supervised practice — including 60 hours of direct supervision. Training may take place anywhere in the world, and must include cultural competency coursework.
DOH may issue an associate facilitator license to someone who has met all requirements except the supervised-practice hours, while that person works toward full licensure. This reduces the catch-22 where trainees need hours to get a license but need a license to get hours.
A clinical facilitator must meet all wellness facilitator requirements, plus hold an active Washington license in one of 20 enumerated health professions — such as physician, psychiatrist, licensed counselor, or social worker. They must also complete an approved course in psychedelic harm reduction and integration.
This dual-tier model means therapists who already hold professional licenses can serve clinical clients, while a broader pool of trained lay practitioners can serve wellness clients. No other state bill currently in committee has this explicit two-tier facilitator structure.
For those interested in entering this field, see our full guide on how to become a psychedelic therapist.
Washington SB 5201 splits program oversight between two agencies — a dual structure Oregon's single-agency model does not use.
The Department of Health (DOH) licenses facilitators and service centers, sets safety standards, and issues rules on dosing, screening, and training approval. The Liquor and Cannabis Board (LCB) handles business licensing and market oversight — drawing on its decade of cannabis regulation experience.
An 11-member Washington Psilocybin Board advises DOH within the department. Six members must be licensed psilocybin facilitators; five are public members. This board also has authority to recommend expanding the program to additional substances starting in 2030.
Washington SB 5201 is the most detailed state psilocybin bill written after Oregon's program went live — and it incorporates several lessons Oregon learned the hard way.
| Feature | Washington SB 5201 | Oregon Measure 109 |
|---|---|---|
| Access tracks | Two: clinical (physician-recommended) + wellness (open access) | One: single supervised-use track, no clinical requirement |
| Diagnosis required? | No for wellness track; physician recommendation for clinical track | No — diagnosis explicitly prohibited as a requirement |
| Facilitator tiers | Two tiers: wellness facilitator and clinical facilitator | One tier: licensed facilitator (no clinical license required) |
| Affordability goal in statute | Yes — SB 5201 findings name affordability as a core purpose | No explicit affordability goal in Measure 109 text |
| Oversight structure | Dual agency: DOH + Liquor and Cannabis Board | Single agency: Oregon Health Authority |
| Future substances | Board can add substances from 2030 onward | Psilocybin only under current law |
| Program status | Pending — bill stalled in 2025 session | Active — service centers operating since 2023 |
| Personal possession | Not decriminalized statewide | Not decriminalized statewide |
When Washington's model fits better (if passed): people who want a medically supervised session tied to a specific diagnosis, or who benefit from the lower-cost group wellness track. When Oregon fits better: you want access now, from a mature program with hundreds of operating facilitators. For Oregon's rules, see the Oregon Measure 109 guide.
Washington SB 5201 stalled in the Senate Labor and Commerce Committee during the 2025 legislative session and did not advance to a floor vote.
Washington SB 5201 drew testimony from a wide range of stakeholders — and criticism came from both directions at once.
Advocates and harm-reduction groups supported the bill's intent but opposed the lack of decriminalization. Organizations like REACH Washington argued the bill would make psilocybin services legal only inside for-profit centers while still criminalizing people who seek access outside the licensed system.
On the other side, the Washington State Medical Association, Washington State Public Health Association, and Washington State Psychiatric Association provided testimony during hearings. Their concerns focused on the readiness of the evidence base and whether the regulatory framework adequately protects people with serious mental illness.
This "too lenient / too restrictive" split is the same dynamic that slowed Oregon's early program. It reflects a real tension: a clinical-only model prices out most users; an open-access model worries clinicians. Washington's two-track structure was designed to thread that needle — but it satisfied neither camp fully in 2025 hearings.
Psilocybin remains a Schedule I controlled substance under federal law, regardless of what Washington State enacts. SB 5201, if it passed, would be a state law only — it would not change federal enforcement authority.
Federal agencies have not targeted state-licensed psilocybin programs in Oregon or Colorado, but the risk is real and not zero. Insurance coverage is also blocked at the federal level: plans will not reimburse psilocybin sessions while the substance is Schedule I.
For the full picture of where psilocybin is and is not legal across the country, see our guide to what psychedelics are legal in the US and the legal status by state tool. For cities in Washington that have passed deprioritization resolutions — including Seattle — see our guide to US cities that decriminalized psilocybin.
Washington SB 5201, the Clinical and Supervised Access to Psilocybin Act, would create a state-licensed program allowing adults 21 and older to use psilocybin in supervised settings. It creates two tracks: a clinical track for people with a physician's support, and a wellness track for adults who want facilitated sessions without a medical diagnosis.
As of mid-2025, Washington SB 5201 stalled in the Senate Labor and Commerce Committee after no executive action was taken on February 21, 2025. The bill did not pass in the 2025 session. Sponsors can reintroduce it in the 2026 session of the Washington State Legislature.
Psilocybin is not legal for recreational or personal use in Washington State. Several cities — including Seattle and Port Townsend — have passed resolutions to deprioritize enforcement, but psilocybin remains a controlled substance under state and federal law. SB 5201 has not yet passed.
Washington SB 5201 adds a clinical track — requiring a physician's recommendation for people with certain mental health conditions — that Oregon's Measure 109 does not have. Washington also explicitly builds affordability into the bill, adds a wellness track for non-clinical use, and places oversight under both the Department of Health and the Liquor and Cannabis Board. Oregon's program covers only a single supervised-use track with no clinical requirement.
Washington SB 5201 is sponsored by Senator Salomon, with co-sponsors including Nobles, Bateman, Trudeau, Lovelett, Frame, Chapman, Hasegawa, Wellman, Holy, King, Saldaña, Schoesler, and Wilson. The companion House bill, HB 1433, was filed by Representative Nicole Macri with 29 co-sponsors.
Under SB 5201, a wellness facilitator must complete an approved training program, a 50-hour in-person practicum, a state exam, and 200 hours of supervised practice including 60 hours of direct supervision. A clinical facilitator must meet all those requirements plus hold a Washington healthcare professional license in one of 20 enumerated health professions and complete an approved psychedelic harm-reduction integration course.
Washington's program has not launched yet. Oregon and Colorado have active licensed programs now. Our booking checklist helps you verify a license, compare costs, and prepare for the day.
Get Washington State SB 5201 — Psilocybin Therapy Act updates
New votes, rules, court rulings, and access changes for Washington State SB 5201 — Psilocybin Therapy Act — delivered when they happen.
← Back to all psychedelic laws
Suggest a tool, topic, or improvement that would make this site more useful.